Atopic dermatitis and asthma: Parallels in the evolution of treatment

Lawrence F. Eichenfield, Jon Hanifin, Lisa A. Beck, Robert F. Lemanske, Hugh A. Sampson, Scott T. Weiss, Donald Y M Leung

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Objectives. To review epidemiologic correlations between asthma and atopic dermatitis (AD), identify common features in disease pathophysiology, and review steps involved in the development of asthma therapy guidelines to assess the appropriateness of a similar process and approach for AD. Methods. A 7-member panel representing specialists in dermatology, allergy, asthma, immunology, and pediatrics from around the United States convened to review the current literature and evolving data on AD. Participants presented reviews to the panel on the epidemiology of asthma and AD, the genetic predisposition to allergic disease, the current understanding of the immunopathophysiology of AD, interrelationships between the pathologic pathways of asthma and AD, evolving treatment concepts and options in AD, and the applicability of the asthma treatment model and how it may be adapted for guideline development for AD. Commentary and criticism were recorded for use in document preparation. Results. There are clear epidemiologic parallels in asthma and AD. Importantly, AD frequently is the first manifestation of an atopic diathesis, which occurs in genetically predisposed individuals and also includes asthma and allergic rhinitis. Up to 80% of children with AD will eventually develop allergic rhinitis or asthma later in childhood. This classic "atopic triad" has numerous pathophysiologic elements in common, including cyclic nucleotide regulatory abnormalities, immune cell alterations, and inflammatory mediators and allergic triggers. New therapeutic options that target underlying immune mechanisms are available, and their place among treatments for AD is becoming established. Guidelines of care have been developed for asthma. The panel noted that the National Institutes of Health/National Heart, Lung, and Blood Institute guidelines for diagnosis and management of asthma, first issued in 1991, had a tremendous positive impact on many aspects of asthma treatment. It not only created a heightened awareness that asthma is a disease of chronic inflammation, but it also provided unified approaches for therapy and opened new areas of basic science and clinical research. In addition, the guidelines spurred interactions among physicians of various specialties and stimulated a great quantity of research in asthma therapy. It is anticipated that AD therapy guidelines would have similar positive outcomes. Conclusions. The panel concluded that, on the basis of current information and evolving therapeutic options, a clear rationale exists to support AD guideline-development. The many parallels between AD and asthma suggest that processes and approaches used for the asthma therapy guidelines would be appropriate for AD.

Original languageEnglish (US)
Pages (from-to)608-616
Number of pages9
JournalPediatrics
Volume111
Issue number3
DOIs
StatePublished - Mar 1 2003

Fingerprint

Atopic Dermatitis
Asthma
Guidelines
Therapeutics
National Heart, Lung, and Blood Institute (U.S.)
Cyclic Nucleotides
Disease Susceptibility
National Institutes of Health (U.S.)
Genetic Predisposition to Disease
Dermatology
Allergy and Immunology
Research

Keywords

  • Allergy
  • Asthma
  • Atopic dermatitis
  • Treatment guidelines

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Eichenfield, L. F., Hanifin, J., Beck, L. A., Lemanske, R. F., Sampson, H. A., Weiss, S. T., & Leung, D. Y. M. (2003). Atopic dermatitis and asthma: Parallels in the evolution of treatment. Pediatrics, 111(3), 608-616. https://doi.org/10.1542/peds.111.3.608

Atopic dermatitis and asthma : Parallels in the evolution of treatment. / Eichenfield, Lawrence F.; Hanifin, Jon; Beck, Lisa A.; Lemanske, Robert F.; Sampson, Hugh A.; Weiss, Scott T.; Leung, Donald Y M.

In: Pediatrics, Vol. 111, No. 3, 01.03.2003, p. 608-616.

Research output: Contribution to journalArticle

Eichenfield, LF, Hanifin, J, Beck, LA, Lemanske, RF, Sampson, HA, Weiss, ST & Leung, DYM 2003, 'Atopic dermatitis and asthma: Parallels in the evolution of treatment', Pediatrics, vol. 111, no. 3, pp. 608-616. https://doi.org/10.1542/peds.111.3.608
Eichenfield LF, Hanifin J, Beck LA, Lemanske RF, Sampson HA, Weiss ST et al. Atopic dermatitis and asthma: Parallels in the evolution of treatment. Pediatrics. 2003 Mar 1;111(3):608-616. https://doi.org/10.1542/peds.111.3.608
Eichenfield, Lawrence F. ; Hanifin, Jon ; Beck, Lisa A. ; Lemanske, Robert F. ; Sampson, Hugh A. ; Weiss, Scott T. ; Leung, Donald Y M. / Atopic dermatitis and asthma : Parallels in the evolution of treatment. In: Pediatrics. 2003 ; Vol. 111, No. 3. pp. 608-616.
@article{bc37a1a7d74c48fbb5d1ad15304ca87a,
title = "Atopic dermatitis and asthma: Parallels in the evolution of treatment",
abstract = "Objectives. To review epidemiologic correlations between asthma and atopic dermatitis (AD), identify common features in disease pathophysiology, and review steps involved in the development of asthma therapy guidelines to assess the appropriateness of a similar process and approach for AD. Methods. A 7-member panel representing specialists in dermatology, allergy, asthma, immunology, and pediatrics from around the United States convened to review the current literature and evolving data on AD. Participants presented reviews to the panel on the epidemiology of asthma and AD, the genetic predisposition to allergic disease, the current understanding of the immunopathophysiology of AD, interrelationships between the pathologic pathways of asthma and AD, evolving treatment concepts and options in AD, and the applicability of the asthma treatment model and how it may be adapted for guideline development for AD. Commentary and criticism were recorded for use in document preparation. Results. There are clear epidemiologic parallels in asthma and AD. Importantly, AD frequently is the first manifestation of an atopic diathesis, which occurs in genetically predisposed individuals and also includes asthma and allergic rhinitis. Up to 80{\%} of children with AD will eventually develop allergic rhinitis or asthma later in childhood. This classic {"}atopic triad{"} has numerous pathophysiologic elements in common, including cyclic nucleotide regulatory abnormalities, immune cell alterations, and inflammatory mediators and allergic triggers. New therapeutic options that target underlying immune mechanisms are available, and their place among treatments for AD is becoming established. Guidelines of care have been developed for asthma. The panel noted that the National Institutes of Health/National Heart, Lung, and Blood Institute guidelines for diagnosis and management of asthma, first issued in 1991, had a tremendous positive impact on many aspects of asthma treatment. It not only created a heightened awareness that asthma is a disease of chronic inflammation, but it also provided unified approaches for therapy and opened new areas of basic science and clinical research. In addition, the guidelines spurred interactions among physicians of various specialties and stimulated a great quantity of research in asthma therapy. It is anticipated that AD therapy guidelines would have similar positive outcomes. Conclusions. The panel concluded that, on the basis of current information and evolving therapeutic options, a clear rationale exists to support AD guideline-development. The many parallels between AD and asthma suggest that processes and approaches used for the asthma therapy guidelines would be appropriate for AD.",
keywords = "Allergy, Asthma, Atopic dermatitis, Treatment guidelines",
author = "Eichenfield, {Lawrence F.} and Jon Hanifin and Beck, {Lisa A.} and Lemanske, {Robert F.} and Sampson, {Hugh A.} and Weiss, {Scott T.} and Leung, {Donald Y M}",
year = "2003",
month = "3",
day = "1",
doi = "10.1542/peds.111.3.608",
language = "English (US)",
volume = "111",
pages = "608--616",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "3",

}

TY - JOUR

T1 - Atopic dermatitis and asthma

T2 - Parallels in the evolution of treatment

AU - Eichenfield, Lawrence F.

AU - Hanifin, Jon

AU - Beck, Lisa A.

AU - Lemanske, Robert F.

AU - Sampson, Hugh A.

AU - Weiss, Scott T.

AU - Leung, Donald Y M

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Objectives. To review epidemiologic correlations between asthma and atopic dermatitis (AD), identify common features in disease pathophysiology, and review steps involved in the development of asthma therapy guidelines to assess the appropriateness of a similar process and approach for AD. Methods. A 7-member panel representing specialists in dermatology, allergy, asthma, immunology, and pediatrics from around the United States convened to review the current literature and evolving data on AD. Participants presented reviews to the panel on the epidemiology of asthma and AD, the genetic predisposition to allergic disease, the current understanding of the immunopathophysiology of AD, interrelationships between the pathologic pathways of asthma and AD, evolving treatment concepts and options in AD, and the applicability of the asthma treatment model and how it may be adapted for guideline development for AD. Commentary and criticism were recorded for use in document preparation. Results. There are clear epidemiologic parallels in asthma and AD. Importantly, AD frequently is the first manifestation of an atopic diathesis, which occurs in genetically predisposed individuals and also includes asthma and allergic rhinitis. Up to 80% of children with AD will eventually develop allergic rhinitis or asthma later in childhood. This classic "atopic triad" has numerous pathophysiologic elements in common, including cyclic nucleotide regulatory abnormalities, immune cell alterations, and inflammatory mediators and allergic triggers. New therapeutic options that target underlying immune mechanisms are available, and their place among treatments for AD is becoming established. Guidelines of care have been developed for asthma. The panel noted that the National Institutes of Health/National Heart, Lung, and Blood Institute guidelines for diagnosis and management of asthma, first issued in 1991, had a tremendous positive impact on many aspects of asthma treatment. It not only created a heightened awareness that asthma is a disease of chronic inflammation, but it also provided unified approaches for therapy and opened new areas of basic science and clinical research. In addition, the guidelines spurred interactions among physicians of various specialties and stimulated a great quantity of research in asthma therapy. It is anticipated that AD therapy guidelines would have similar positive outcomes. Conclusions. The panel concluded that, on the basis of current information and evolving therapeutic options, a clear rationale exists to support AD guideline-development. The many parallels between AD and asthma suggest that processes and approaches used for the asthma therapy guidelines would be appropriate for AD.

AB - Objectives. To review epidemiologic correlations between asthma and atopic dermatitis (AD), identify common features in disease pathophysiology, and review steps involved in the development of asthma therapy guidelines to assess the appropriateness of a similar process and approach for AD. Methods. A 7-member panel representing specialists in dermatology, allergy, asthma, immunology, and pediatrics from around the United States convened to review the current literature and evolving data on AD. Participants presented reviews to the panel on the epidemiology of asthma and AD, the genetic predisposition to allergic disease, the current understanding of the immunopathophysiology of AD, interrelationships between the pathologic pathways of asthma and AD, evolving treatment concepts and options in AD, and the applicability of the asthma treatment model and how it may be adapted for guideline development for AD. Commentary and criticism were recorded for use in document preparation. Results. There are clear epidemiologic parallels in asthma and AD. Importantly, AD frequently is the first manifestation of an atopic diathesis, which occurs in genetically predisposed individuals and also includes asthma and allergic rhinitis. Up to 80% of children with AD will eventually develop allergic rhinitis or asthma later in childhood. This classic "atopic triad" has numerous pathophysiologic elements in common, including cyclic nucleotide regulatory abnormalities, immune cell alterations, and inflammatory mediators and allergic triggers. New therapeutic options that target underlying immune mechanisms are available, and their place among treatments for AD is becoming established. Guidelines of care have been developed for asthma. The panel noted that the National Institutes of Health/National Heart, Lung, and Blood Institute guidelines for diagnosis and management of asthma, first issued in 1991, had a tremendous positive impact on many aspects of asthma treatment. It not only created a heightened awareness that asthma is a disease of chronic inflammation, but it also provided unified approaches for therapy and opened new areas of basic science and clinical research. In addition, the guidelines spurred interactions among physicians of various specialties and stimulated a great quantity of research in asthma therapy. It is anticipated that AD therapy guidelines would have similar positive outcomes. Conclusions. The panel concluded that, on the basis of current information and evolving therapeutic options, a clear rationale exists to support AD guideline-development. The many parallels between AD and asthma suggest that processes and approaches used for the asthma therapy guidelines would be appropriate for AD.

KW - Allergy

KW - Asthma

KW - Atopic dermatitis

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=0037339662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037339662&partnerID=8YFLogxK

U2 - 10.1542/peds.111.3.608

DO - 10.1542/peds.111.3.608

M3 - Article

C2 - 12612244

AN - SCOPUS:0037339662

VL - 111

SP - 608

EP - 616

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 3

ER -